Patent SG-11201903667X-A (SG)
Title: Novel dosage regimen
Inventor: MORISSET VALERIE
IPC: A61K31/401
Filed: 2017-11-02
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 May 2018 (11.05.2018) WIPO I PCT 111111111111011010101111101111010 0111MOMIll OWE 11101111 (10) International Publication Number WO 2018/085521 A9 W O 20 18/0855 21 A9 (51) International Patent Classification: A61K 31/401 (2006.01) A61P 29/00 (2006.01) A61P 25/02 (2006.01) (21) International Application Number: PCT/US2017/059691 (22) International Filing Date: 02 November 2017 (02.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/416,392 02 November 2016 (02.11.2016) US 62/515,836 06 June 2017 (06.06.2017) US (71) Applicants: BIOGEN INC. [US/US]; 225 Binney Street, Cambridge, MA 02142 (US). BIOGEN MA INC. [US/US]; 250 Binney Street, Cambridge, MA 02142 (US). (72) Inventors: MORISSET, Valerie; c/o Biogen Inc., 225 Binney Street, Cambridge, MA 02142 (US). NAIK, Hi- manshu; c/o Biogen Inc., 225 Binney Street, Cambridge, MA 02142 (US). DUNBAR, Joi; c/o Biogen Inc., 225 Binney Street, Cambridge, MA 02142 (US). VERSAVEL, Mark; c/o Biogen Inc., 225 Binney Street, Cambridge, MA 02142 (US). (74) Agent: HALSTEAD, David, P. et al.; Foley Hoag LLP, Seaport West, 155 Seaport Blvd., Boston, MA 02210-2600 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (88) Date of publication of the international search report: 07 June 2018 (07.06.2018) (48) Date of publication of this corrected version: 05 July 2018 (05.07.2018) (15) Information about Correction: see Notice of 05 July 2018 (05.07.2018) (54) Title: NOVEL DOSAGE REGIMEN (57) : The present invention is directed to a novel method of treating a disease or condition mediated by modulation of Nav1.7 and other voltage-gated sodium channel subtypes, such as pain, in particular neuropathic pain, most particularly trigeminal neuralgia.